Affiliation:
1. Peking University People’s Hospital
2. Eye Institute of Shandong
3. Department of Ophthalmology, Qilu Hospital of Shandong
Abstract
Abstract
Background
The efficacy of concurrent intravitreal Ranibizumab (IVR) and extended-release dexamethasone injections (Dex-I) in patients with naïve and refractory retinal vein occlusion macular edema (RVO-ME) was not well investigated previously.
Methods
This was a prospective, interventional, and open-label case series design. There were two groups: naïve and refractory patients (received ≥ 5 times of previous IVR within one year prior to enrollment) enrolled. Patients received IVR and Dex-I concurrently. IVR and Dex-I were given PRN. The mean change in best-corrected visual acuity (BCVA) was measured as main outcome.
Results
63 patients (63 eyes) completed the entire follow-up (31 naïve and 32 refractory patients). At month 12, the change in BCVA was greater in the naïve group than in the refractory group (19.67 ± 11.7 (95%CI: 15.03,24.31) letters vs. 11.74 ± 11.18 (95%CI:7.32,16.16) letters, P = 0.014). There was no difference between the two groups of mean macular thickness reduction. (364.26 ± 215.29 (95%CI: 279.09,449.43)µm v.s. 410.19 ± 204.34 (95%CI: 329.35,491.02)µm, P = 0.43). The mean co-injection numbers were 2.52 ± 0.58 (95%CI:2.29,2.75) and 2.33 ± 0.55(95%CI:2.11,2.55) in both groups (P = 0.24). The retreatment interval was 115.81 ± 13.79 (95%CI: 110.36,121.27) days and 122.74 ± 14.06(95%CI: 119.93,133.56) days in both groups (P = 0.073). There was no significant difference in the incidence of glaucoma or the progression of cataracts between the two groups.
Conclusion
In both naïve and refractory RVO-ME patients, IVR combined with Dex-I was effective. The initial combination therapy for naïve patients demonstrated more efficient improvement in BCVA and may reduce total injection numbers.
Trial registration: this study was registered with the identifier ChiCTR-INR-17011877 at https://www.chictr.org.cn/
Publisher
Research Square Platform LLC
Reference40 articles.
1. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia;Rogers S;Ophthalmology,2010
2. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors;Song P;J Glob Health,2019
3. The burden of disease of retinal vein occlusion: review of the literature;Laouri M;Eye (Lond),2011
4. Interventions for branch retinal vein occlusion: an evidence-based systematic review;McIntosh RL;Ophthalmology,2007
5. Hirano Y, Suzuki N, Tomiyasu T, Kurobe R, Yasuda Y, Esaki Y, Yasukawa T, Yoshida M, Ogura Y. Multimodal Imaging of Microvascular Abnormalities in Retinal Vein Occlusion.J Clin Med2021, 10(3).